Heron Therapeutics is a commercial-stage biotechnology company. Co. is developing solutions that apply its science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer. Co.'s main commercial product, SUSTOL, is for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. Co.'s other commercial product, CINVANTI, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. The HRTX stock yearly return is shown above.
The yearly return on the HRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|